Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT05427071

Recruiting

Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy (MaCTAD)

Breast Neoplasm | Chemotherapy Effect
NCT05302336

Recruiting

AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

Breast Cancer | Chemotherapeutic Toxicity
NCT05292742

Recruiting

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Breast Cancer | Adjuvant Therapy
NCT05135013

Not yet recruiting

The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study

Observational Study
NCT05044689

Recruiting

Case Control Study to Identify Modifiable Risk Factors for Colorectal and Breast Cancer in Nigeria

Breast Cancer | Colorectal Cancer
NCT05035836

Recruiting

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Breast Cancer | HER2-positive
NCT04669873

Recruiting

Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery (LAPIDARY)

Malignant Neoplasm of Breast
NCT04654208

Recruiting

Swedish Ibrance Registries Insights (SIRI) (SIRI)

Malignant Neoplasm of Breast
NCT04424732

Recruiting

SBRT for Breast Cancer Oligometastases

Breast Neoplasm Malignant Female
NCT03728829

Recruiting

Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer

Prospective | Observational
NCT04489173

Completed

TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer (TIBET)

Breast Neoplasm | Chemotherapy Effect
NCT04251533

Terminated

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)

Triple Negative Breast Neoplasms
NCT03742102

Active, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

Triple Negative Breast Neoplasms
NCT06627582

Active, not recruiting

A Study on Pain After Breast Reconstruction

Breast Reconstruction | Mastectomy | Postmastectomy Pain | Mastectomy Patient | Mastectomy and Breast Reconstruction | Breast Reconstruction After Mastectomy
NCT03006172

Active, not recruiting

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Breast Cancer | Solid Tumor
NCT03523585

Completed

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Breast Cancer
NCT07418411

Completed

Additional Imaging Methods for Assessing Axillary Lymph Node Involvement in Breast Cancer

Breast Cancer | Axillary Lymph Node Metastasis
NCT01853748

Completed

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Breast Cancer
NCT02624973

Active, not recruiting

PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC)

Breast Cancer
NCT01796197

Completed

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Breast Cancer
NCT06833723

Active, not recruiting

Development of a Multi-omics Prediction Model for Immunotherapy Response in Triple-Negative Breast Cancer Subtypes

Breast Neoplasms
NCT06570811

Completed

Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients

Breast Cancer | Chemotherapeutic Toxicity
NCT07092475

Withdrawn

The Impact of Intraoperative Methadone on Postoperative Opioid Use

Breast Cancer | Opioid Use
NCT05945927

Completed

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Breast Cancer
NCT03944499

Completed

Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.

Breast Cancer | Solid Tumor
NCT03248492

Terminated

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Breast Cancer
NCT05134922

Available

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

Breast Neoplasm Malignant Female
NCT05739175

Completed

The Effect of the Mobile Application-based Support Program on the Outcomes of Breast Cancer Patients in the Pandemic

Breast Cancer | Nursing
NCT04289805

Terminated

Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) (fAMHOPE)

Breast Neoplasm Malignant Female
NCT06382441

Completed

A Tele-exercise Program for Breast Cancer Survivors

Behavior, Health
NCT05192525

Completed

The Effects of a Nurse-led MHealth Program for Symptom Self-management of Breast Cancer Patients Undergoing Chemotherapy (mChemo)

Breast Cancer | Chemotherapeutic Toxicity
NCT04088877

Completed

Rise Up After Breast Cancer (RISE-UP)

Breast Cancer | Body Image
NCT05901142

Active, not recruiting

Prehabilitation and RecOVERy From Surgery for Breast Cancer Study (PROVERB)

Exercise | Breast Neoplasm Female
NCT03425656

Completed

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer

Malignant Neoplasm of Breast
NCT01996267

Active, not recruiting

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (TRAIN-2)

Breast Cancer | HER2 Positive
NCT03280836

Completed

Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy (WISER-NET)

Physical Activity | Breast Neoplasm
NCT06134570

Enrolling by invitation

ALDH1A1 Expression in Invasive Mammary Carcinoma

Breast Cancer
NCT04562233

Terminated

Breast Cancer and Resistance Exercise Program (B-REP)

Breast Cancer | Resistance Training
NCT05159778

Completed

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Malignant Neoplasm of Breast
NCT05128617

Completed

Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study (PROTECT-06)

Breast Cancer
NCT03860740

Completed

Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients (EFIK)

Breast Cancer | Luminal B
NCT00976131

Completed

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Breast Cancer
NCT02720185

Terminated

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Breast Neoplasms | Triple Negative Breast Neoplasms
NCT01702571

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer
NCT02763228

Completed

Physical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer Survivors

Breast Cancer | Physical Activity
NCT02595372

Completed

Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy

Cancer of the Breast
NCT00464646

Completed

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Breast Cancer
NCT03908528

Completed

Alpha-Lipoic Acid in Breast Cancer Patients

Breast Cancer | Chemotherapeutic Toxicity
NCT04882371

Completed

Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer

Breast Cancer | Chemotherapy Effect
NCT03289819

Completed

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC (NIB)

Malignant Neoplasm of Breast

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations